In response to RFA No. 10-NIH-NCI-DRCCA Community Clinical Oncology Program, National Cancer Institute (CCOP) the Carle Clinic Association, Urbana Illinois, makes application to be designated a CCOP in East Central Illinois. As the fourteenth largest private medical practice group in the United States the Carle Clinic Association has a fully developed community cancer center program. The Carle Clinic is one of Illinois' largest downstate referral centers for all forms of medical care seeing over 1200 outpatients each day. The Carle Clinic is adjacent to the 376 bed Carle Foundation Hospital which has a dedicated 24 bed oncology ward. The Carle complex registered 704 analytic cancer cases in 1981. Since 1976 the Carle Clinic has been in active participant in the Cancer Control Program of the Eastern Cooperative Oncology Group, registering 233 patients on national protocols to date for an average of 42 patients per year. In making this application for a CCOP award, the Carle Cancer Center, composed of four hematologist/oncologists and two radiation therapists, states that it will register at least 60 patients per year on approved ECOG protocols and 10 patients per year on the protocols of the Illinois Cancer Council (the comprehensive cancer center for the State of Illinois). In addition to increasing the cancer center's protocol activities, Carle will expand cancer control activities in the areas of public and professional education within our service area, and will establish a multiple site cancer detection facility. If granted this award, the Carle Cancer Center will endeavor to facilitate the transfer of technology in modern methods of cancer detection and management to the citizens and health professionals of our East Central Illinois region. We will further upgrade our already established data management office and comply with all terms outlined in the RFA for receiving this award. It is our belief that a cancer center should participate in clinical research protocols, public and professional education, and cancer prevention and detection as well as provide the highest standards of clinical cancer care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035195-03
Application #
3557613
Study Section
(SRC)
Project Start
1983-09-15
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Carle Clinic Association, P C
Department
Type
DUNS #
075606517
City
Urbana
State
IL
Country
United States
Zip Code
61801
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Zhao, Yujie; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. J Thorac Oncol 10:172-80
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27

Showing the most recent 10 out of 164 publications